Biblio
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4(16):3977-3989.
Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis. Bone Marrow Transplant. 2023.
. CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018.
EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020.
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810-2820.
Gut Microbiota Predict Pulmonary Infiltrates After Allogeneic Hematopoietic Cell Transplantation. Am J Respir Crit Care Med. 2016.
. HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE IN PATIENTS WITH PRIOR COVID-19 INFECTION. Transplant Cell Ther. 2021.
Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1125:121711.
. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma. Biol Blood Marrow Transplant. 2020.
Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse. Sci Transl Med. 2023;15(706):eabq0476.